Nedosiran: A Promising Treatment for Primary Hyperoxaluria

What is Nedosiran?

Nedosiran, also known as DCR-PHXC, is an investigational drug being developed to treat a rare genetic condition called Primary Hyperoxaluria (PH)1. It's important to understand that as an investigational drug, nedosiran is still being studied and is not yet approved for general use by regulatory agencies.

What Conditions Does Nedosiran Treat?

Nedosiran is specifically designed to treat Primary Hyperoxaluria (PH), a rare genetic disorder that affects the kidneys. There are three main types of PH that nedosiran may potentially treat2:

• Primary Hyperoxaluria Type 1 (PH1): This is the most common and severe form of PH.
• Primary Hyperoxaluria Type 2 (PH2)
• Primary Hyperoxaluria Type 3 (PH3)

In Primary Hyperoxaluria, the body produces too much of a substance called oxalate. This excess oxalate can combine with calcium to form kidney stones and can also damage the kidneys over time. Nedosiran aims to reduce the production of oxalate in the body, potentially slowing or preventing kidney damage in people with PH12.

How is Nedosiran Administered?

Nedosiran is given as a subcutaneous injection, which means it's injected just under the skin. The dosing schedule and amount can vary depending on the patient's age and weight1:

• For adults and adolescents (aged 12-17 years) weighing 50 kilograms (kg) or more: 170 milligrams (mg) once a month
• For adults and adolescents weighing less than 50 kg: 136 mg once a month
• For children aged 6 to 11 years: 3.5 mg per kg of body weight monthly, not exceeding 170 mg

The injection is typically given in the thigh or abdomen. In some cases, after proper training, patients or their caregivers may be able to administer the medication at home1.

Clinical Trials and Research

Nedosiran is currently being studied in clinical trials to evaluate its safety and effectiveness. These trials involve different age groups and focus on various aspects of the drug's performance2:

• Pediatric Study: One ongoing study is looking at nedosiran in children from birth to 11 years old who have Primary Hyperoxaluria and relatively good kidney function.
• Expanded Access Program: Another program is providing access to nedosiran for eligible patients with PH1 until the drug becomes commercially available or the program is terminated.

These studies aim to understand how well nedosiran works in reducing oxalate levels in the body and its overall impact on kidney function2.

Safety and Monitoring

As with any investigational drug, the safety of nedosiran is being closely monitored. During clinical trials, researchers are tracking various safety measures2:

• Adverse events (side effects)
• Changes in vital signs (temperature, pulse rate, respiratory rate, blood pressure)
• Changes in ECG (heart rhythm test) results
• Changes in laboratory test results (blood tests, urine tests)
• Physical examination findings

Patients participating in nedosiran trials are typically required to attend regular clinic visits for these safety assessments12.

Potential Benefits

While the full benefits of nedosiran are still being studied, researchers are looking at several potential positive outcomes2:

• Reduced oxalate levels: The main goal is to lower the amount of oxalate in urine and blood.
• Improved kidney function: By reducing oxalate, nedosiran may help preserve kidney function.
• Fewer kidney stones: Lower oxalate levels may lead to fewer kidney stone events.
• Better quality of life: Researchers are assessing whether nedosiran can improve overall quality of life for patients with PH.

It's important to note that as an investigational drug, the full range of benefits and potential risks of nedosiran are still being determined through ongoing research12.